Hemab Therapeutics Inc. Common Stock

COAG | NASDAQ

Price Alert Chart Builder DCF Calculator

$41.16

-$0.29 (-0.70%)

Nov 2, 2026, 3:53 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.70%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

26.4

+1.0 pts

Fundamentals Weak

Market Sentiment Bullish

Moat None

Sector Rank #882/1028 (Top 86%)

Full Analysis

Key Statistics

Market Data

Market Cap $1.92B

1D Range

39.96 42.91

52W Range

24.98 54.94

Valuation (TTM)

PE -31.59

PB 4.26

EV/EBITDA -29.80

Valuation (NTM)

Forward PE N/A

Forward PEG 0.33

Price Target $51.40

Cash Flow

FCF Yield -2.3%

SBC Adj. FCF Yield -2.4%

SBC Impact -3.0%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -10.0%

ROE -36.6%

ROIC -10.9%

Financial Health

Net Cash

$457.46M

Current Ratio 35.85

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission...

Sector Healthcare

Industry Biotechnology

Employees 59

IPO Date May 1, 2026

Website www.hemab.com

Fiscal Year January - December

Full Company Profile

Latest News

1 month ago · globenewswire.com

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board

2 months ago · globenewswire.com

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare professional in the U.S. last year.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$50.00

Upside

+21.48%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞